



## **MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza®**

July 27, 2018

WESTLAKE VILLAGE, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- **MannKind Corporation**(Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a distribution agreement for Afrezza® with Tanner Pharma Group, a global provider of integrated specialty access solutions. The agreement names Tanner as a distributor of Afrezza® outside of the United States in regions the product is not yet registered. Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

"Al Mann had a vision of making Afrezza available to all people living with diabetes around the world and this agreement helps accelerate that access to Afrezza on a named patient access basis in underserved international markets," said Michael Castagna, Chief Executive Officer of MannKind. "Our partnership with Tanner Pharma to distribute Afrezza provides us a strong partner with a track record of success in working with physicians, hospitals and ministries of health to provide medicine that is not currently available in their country."

The distribution will be managed by TannerGAP, Inc. ("TannerGAP"), a wholly owned subsidiary of Tanner Pharma Group.

"We are pleased to partner with MannKind in helping fulfill the demand for Afrezza in countries outside the U.S.," said Banks Bourne, Chairman and Founder of Tanner Pharma Group.

To obtain additional details about the Tanner program for Afrezza, please call +1 704 552 8408 or email [mannkind@tannerpharma.com](mailto:mannkind@tannerpharma.com).

### **About Afrezza®**

Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit [www.afrezza.com](http://www.afrezza.com).

### **About MannKind Corporation**

MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit [www.mannkindcorp.com](http://www.mannkindcorp.com).

### **About Tanner Pharma Group**

For over 15 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners. Companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programs, and source comparator drugs for clinical trials and bioanalysis. For more information, visit [www.tannerpharma.com](http://www.tannerpharma.com).

### **Company Contact:**

Rose Alinaya  
SVP, Investor Relations  
818-661-5000  
[ir@mannkindcorp.com](mailto:ir@mannkindcorp.com)

 [Primary Logo](#)

Source: MannKind